As its name might suggest, California-based Glaukos is involved in the glaucoma space. Specifically, the company describes its focus as "the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma."
For some context, the S&P 500 index returned 3.2% in February and has returned 3.9% over the last year.
While Glaukos stock had solid momentum throughout February, we can attribute the bulk of its robust performance last month to the company's Feb. 27 release of fourth-quarter results that were better than anticipated. Shares popped 9.3% the next day.
In the quarter, net revenue surged 30% year over year to $54.1 million, and earnings per share (EPS) jumped 33% to $0.04, crushing Wall Street's consensus estimate of a $0.13 loss per share.
Here's how Glaukos stock has performed since its June 2015 initial public offering (IPO).
For full-year 2019, Glaukos guided for net revenue of $220 million to $230 million, which represents growth of 21.3% to 26.9% year over year.